Urine diacetylspermine as a novel tumor marker

Koji Yamaguchi, Tsunehisa Kaku, Munechika Enjoji, Masato Kato, Motoaki Anai, Masao Kawakita, Naotaka Hamasaki, Masao Tanaka

Research output: Contribution to journal › Review article

Abstract

A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies. The urine marker increased together with recurrence, suggesting a recurrence monitoring marker at the outpatient ward. Regarding hepatocellular carcinoma, the sensitivity of the urine marker was as high as conventional markers such as AFP and PIVKA II. Synchronous examination of serum and urine markers showed a higher sensitivity than the single serum or urine marker for hepatocellular carcinoma. The sensitivity for non-advanced hepatocellular carcinoma was 50%, while that for advanced hepatocellular carcinoma was 83%. The urine marker may be useful to detect non-advanced hepatocellular carcinoma. The sensitivity for lung cancer was 83% and that for Stage I or II was 82%. Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia. The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%. These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.

Original languageEnglish
Pages (from-to)130-135
Number of pages6
JournalRinsho byori. The Japanese journal of clinical pathology
Volume53
Issue number2
Publication statusPublished - Feb 2005

Fingerprint

Tumor Biomarkers
Urine
Hepatocellular Carcinoma
Carcinoma
Neoplasms
Lung Neoplasms
Recurrence
N',N''-diacetylspermine
Outpatients
Biomarkers
Lung
Liver
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yamaguchi, K., Kaku, T., Enjoji, M., Kato, M., Anai, M., Kawakita, M., ... Tanaka, M. (2005). Urine diacetylspermine as a novel tumor marker. Rinsho byori. The Japanese journal of clinical pathology, 53(2), 130-135.

Urine diacetylspermine as a novel tumor marker. / Yamaguchi, Koji; Kaku, Tsunehisa; Enjoji, Munechika; Kato, Masato; Anai, Motoaki; Kawakita, Masao; Hamasaki, Naotaka; Tanaka, Masao.

In: Rinsho byori. The Japanese journal of clinical pathology, Vol. 53, No. 2, 02.2005, p. 130-135.

Research output: Contribution to journal › Review article

Yamaguchi, K, Kaku, T, Enjoji, M, Kato, M, Anai, M, Kawakita, M, Hamasaki, N & Tanaka, M 2005, 'Urine diacetylspermine as a novel tumor marker', Rinsho byori. The Japanese journal of clinical pathology, vol. 53, no. 2, pp. 130-135.
Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M et al. Urine diacetylspermine as a novel tumor marker. Rinsho byori. The Japanese journal of clinical pathology. 2005 Feb;53(2):130-135.
Yamaguchi, Koji ; Kaku, Tsunehisa ; Enjoji, Munechika ; Kato, Masato ; Anai, Motoaki ; Kawakita, Masao ; Hamasaki, Naotaka ; Tanaka, Masao. / Urine diacetylspermine as a novel tumor marker. In: Rinsho byori. The Japanese journal of clinical pathology. 2005 ; Vol. 53, No. 2. pp. 130-135.
@article{1ebb7fdcfc784597ad0211de55e6c4c3,
title = "Urine diacetylspermine as a novel tumor marker",
abstract = "A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies. The urine marker increased together with recurrence, suggesting a recurrence monitoring marker at the outpatient ward. Regarding hepatocellular carcinoma, the sensitivity of the urine marker was as high as conventional markers such as AFP and PIVKA II. Synchronous examination of serum and urine markers showed a higher sensitivity than the single serum or urine marker for hepatocellular carcinoma. The sensitivity for non-advanced hepatocellular carcinoma was 50{\%}, while that for advanced hepatocellular carcinoma was 83{\%}. The urine marker may be useful to detect non-advanced hepatocellular carcinoma. The sensitivity for lung cancer was 83{\%} and that for Stage I or II was 82{\%}. Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia. The sensitivity for ovarian carcinoma was 100{\%}, while that for benign ovarian tumor was 0{\%}. These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.",
author = "Koji Yamaguchi and Tsunehisa Kaku and Munechika Enjoji and Masato Kato and Motoaki Anai and Masao Kawakita and Naotaka Hamasaki and Masao Tanaka",
year = "2005",
month = "2",
language = "English",
volume = "53",
pages = "130--135",
journal = "Rinsho byori. The Japanese journal of clinical pathology",
issn = "0047-1860",
publisher = "Nihon Rinsho Byori Gakkai",
number = "2",

}

TY - JOUR

T1 - Urine diacetylspermine as a novel tumor marker

AU - Yamaguchi, Koji

AU - Kaku, Tsunehisa

AU - Enjoji, Munechika

AU - Kato, Masato

AU - Anai, Motoaki

AU - Kawakita, Masao

AU - Hamasaki, Naotaka

AU - Tanaka, Masao

PY - 2005/2

Y1 - 2005/2

N2 - A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies. The urine marker increased together with recurrence, suggesting a recurrence monitoring marker at the outpatient ward. Regarding hepatocellular carcinoma, the sensitivity of the urine marker was as high as conventional markers such as AFP and PIVKA II. Synchronous examination of serum and urine markers showed a higher sensitivity than the single serum or urine marker for hepatocellular carcinoma. The sensitivity for non-advanced hepatocellular carcinoma was 50%, while that for advanced hepatocellular carcinoma was 83%. The urine marker may be useful to detect non-advanced hepatocellular carcinoma. The sensitivity for lung cancer was 83% and that for Stage I or II was 82%. Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia. The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%. These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.

AB - A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies. The urine marker increased together with recurrence, suggesting a recurrence monitoring marker at the outpatient ward. Regarding hepatocellular carcinoma, the sensitivity of the urine marker was as high as conventional markers such as AFP and PIVKA II. Synchronous examination of serum and urine markers showed a higher sensitivity than the single serum or urine marker for hepatocellular carcinoma. The sensitivity for non-advanced hepatocellular carcinoma was 50%, while that for advanced hepatocellular carcinoma was 83%. The urine marker may be useful to detect non-advanced hepatocellular carcinoma. The sensitivity for lung cancer was 83% and that for Stage I or II was 82%. Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia. The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%. These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=20844440535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844440535&partnerID=8YFLogxK

M3 - Review article

C2 - 15796046

AN - SCOPUS:20844440535

VL - 53

SP - 130

EP - 135

JO - Rinsho byori. The Japanese journal of clinical pathology

JF - Rinsho byori. The Japanese journal of clinical pathology

SN - 0047-1860

IS - 2

ER -

Access to Document